Pure Global
NCT06272747

A Phase I Study of XH-S003 in Healthy Volunteers

A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of XH-S003 After Single Ascending Doses, Multiple Ascending Doses and Evaluation of Food Effects in Healthy Volunteers
S-Infinity Pharmaceuticals Co., Ltd·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Adults
Drug/Device/Intervention
XH-S003
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
S-Infinity Pharmaceuticals Co., Ltd
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Feb 22, 2024
End date
Oct 30, 2024
Enrollment
44 participants
Primary outcome

Number of participants with adverse events (AEs),Number of participants with adverse events (AEs)

Summary

The purpose of the study is to assess the safety, tolerability and pharmacokinetics of
 XH-S003 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending
 dose) studies. In addition, this study evaluates the food effects of XH-S003.

ICD-10 classifications
ObesityHealthy person accompanying sick personObesity, unspecifiedRoutine general health check-up of inhabitants of institutionsLifestyle-related condition
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06272747
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06272747 through Pure Global AI's free database. This Phase 1 trial is sponsored by S-Infinity Pharmaceuticals Co., Ltd and is currently Not yet recruiting. The study focuses on Healthy Adults. Target enrollment is 44 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.